These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6400156)

  • 1. Immunotherapy of bladder tumors.
    Herr HW
    Uremia Invest; 1984-1985; 8(3-4):257-61. PubMed ID: 6400156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of superficial bladder cancer.
    Shapiro A; Kadmon D; Catalona WJ; Ratliff TL
    J Urol; 1982 Nov; 128(5):891-4. PubMed ID: 6184490
    [No Abstract]   [Full Text] [Related]  

  • 3. [Trials of immunotherapy in tumors of the urinary tract].
    Corrado F; Pizza G
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():659-66. PubMed ID: 6336141
    [No Abstract]   [Full Text] [Related]  

  • 4. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
    Morales A; Eidinger D; Bruce AW
    J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
    Flamm J; Bucher A; Höltl W; Albrecht W
    J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
    Jurincic-Winkler C; Engelmann U; Beuth J; Klippel KF
    Zentralbl Bakteriol; 1995 Oct; 282(4):409-15. PubMed ID: 9810664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effect of IL-6 on transitional cell carcinoma of the bladder. Insight into mechanisms of bacillus Calmette-Guerin immunotherapy.
    Alexandroff AB; Black J; Esuvaranathan K; James K
    Biochem Soc Trans; 1997 May; 25(2):270S. PubMed ID: 9191314
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
    Flamm J; Bucher A
    Br J Urol; 1991 Jan; 67(1):70-3. PubMed ID: 1993279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Byrne H; Stone L
    Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
    Lamm DL; DeHaven JI; Riggs DR; Ebert RF
    J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy: The Wave of the Future in Bladder Cancer?
    Petrylak DP
    Clin Genitourin Cancer; 2017 Jun; 15(3S):S3-S17. PubMed ID: 28633756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
    Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
    Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of murine transitional cell carcinoma.
    Lamm DL; Reichert DF; Harris SC; Lucio RM
    J Urol; 1982 Nov; 128(5):1104-8. PubMed ID: 6757465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.
    Torti FM; Shortliffe LD; Williams RD; Pitts WC; Kempson RL; Ross JC; Palmer J; Meyers F; Ferrari M; Hannigan J
    J Clin Oncol; 1988 Mar; 6(3):476-83. PubMed ID: 3280742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
    Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
    J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy of superficial bladder cancer].
    Schmitz-Dräger BJ; Schattka SO; Ebert T
    Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors.
    Flam TA; Chopin DK; Leleu C; Abbou CC; Steg A; Deslignères S; Boccon-Gibod L
    Eur Urol; 1990; 17(4):338-42. PubMed ID: 1694766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.